Aim: This prospective study aimed to envisage the putative prognostic significance of clinical and hematologic parameters in advanced non-small-cell lung cancer patients treated with nivolumab. Materials & methods: Correlations of several parameters with disease control and survival outcomes were provided. Results: A total of 54 patients were included. An ECOG performance status 0-1, the lack of liver and bone metastases and a timeframe from the last systemic treatment ≥4 months correlated with better disease control. The same was observed for baseline low levels of white blood cells and neutrophils, for high levels of NK cells and a neutrophil/lymphocyte ratio <4. The mentioned parameters were also associated with longer overall survival. Conclusion: Nivolumab efficacy in non-small-cell lung cancer patients is influenced by clinicopathological parameters and specific leucocyte subsets.

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab / Facchinetti, F.; Veneziani, M.; Buti, S.; Gelsomino, F.; Squadrilli, A.; Bordi, P.; Bersanelli, M.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mazzaschi, G.; Leonardi, F.; Quaini, F.; Ardizzoni, A.; Missale, G.; Tiseo, M.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 10:8(2018), pp. 681-694. [10.2217/imt-2017-0175]

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab

Buti S.;Bersanelli M.;Mazzaschi G.;Quaini F.;Missale G.;Tiseo M.
2018-01-01

Abstract

Aim: This prospective study aimed to envisage the putative prognostic significance of clinical and hematologic parameters in advanced non-small-cell lung cancer patients treated with nivolumab. Materials & methods: Correlations of several parameters with disease control and survival outcomes were provided. Results: A total of 54 patients were included. An ECOG performance status 0-1, the lack of liver and bone metastases and a timeframe from the last systemic treatment ≥4 months correlated with better disease control. The same was observed for baseline low levels of white blood cells and neutrophils, for high levels of NK cells and a neutrophil/lymphocyte ratio <4. The mentioned parameters were also associated with longer overall survival. Conclusion: Nivolumab efficacy in non-small-cell lung cancer patients is influenced by clinicopathological parameters and specific leucocyte subsets.
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab / Facchinetti, F.; Veneziani, M.; Buti, S.; Gelsomino, F.; Squadrilli, A.; Bordi, P.; Bersanelli, M.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Mazzaschi, G.; Leonardi, F.; Quaini, F.; Ardizzoni, A.; Missale, G.; Tiseo, M.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 10:8(2018), pp. 681-694. [10.2217/imt-2017-0175]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2862507
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 25
social impact